Puretech Ownership
Product Candidate
Initial Indication(s)
Stage of Development
72.9% Equity
ENT-100

Oral delivery of biologics, vaccines and other drugs

Preclinical
Engineering hydrogels to enable oral delivery of biologics

Entrega is focused on the oral delivery of biologics, vaccines and other drugs that are otherwise not efficiently absorbed when taken orally. Entrega believes oral administration thus represents an ideal administration approach for this increasingly large class of therapies reshaping many areas of medicine, including the treatment of diabetes.

Our technology platform is an innovative approach to oral delivery which uses a proprietary, customizable hydrogel dosage form to control local fluid microenvironments in the GI tract to both enhance absorption and reduce the variability of drug exposure. To validate our technology, we generated proof-of-concept data demonstrating delivery of therapeutic peptides into the bloodstream of large animals.

  • Program Discovery Process by the PureTech Team
    • PureTech was interested in enabling the oral administration of biologics, which has been a long-standing problem in drug development. PureTech engaged with leading experts in drug delivery, including Robert Langer, ScD, David H Koch Institute Professor at MIT, and screened over 100 technologies and the initial platform was licensed from Samir Mitragotri, PhD, professor of chemical engineering at UC Santa Barbara. PureTech later enhanced this platform with intellectual property developed by its team.
    • Other scientific and business advisors include Colin Gardner, PhD, former chief scientific officer of Transform Pharmaceuticals, former senior vice president of research and site head at Johnson & Johnson and formerly VP of pharmaceutical R&D at Merck & Co., Inc.; Robert Armstrong, PhD, cofounder and chief executive officer of Boston Pharmaceuticals; and Mr Howie Rosen, former President of ALZA.
  • Innovative Approach to Solving the Problem
    • Entrega is focused on the oral delivery of biologics, vaccines and other drugs that are otherwise not efficiently absorbed when taken orally. The vast majority of biologic drugs, including peptides, proteins and other macromolecules, are currently administered by injection, which can present challenges for healthcare delivery and compliance with treatment regimes. Entrega believes oral administration thus represents an ideal administration approach for this increasingly large class of therapies reshaping many areas of medicine, including the treatment of diabetes.
    • Entrega’s technology platform is an innovative approach to oral delivery which uses a proprietary, customization hydrogel dosage form to control local fluid microenvironments in the gastrointestinal tract in an effort to both enhance absorption and reduce the variability of drug exposure.
  • Milestones Achieved
    • To validate its technology, Entrega generated POC preclinical data demonstrating delivery of therapeutic peptides into the bloodstream of large animals.
    • Entrega received $5 million in equity and research funding from Eli Lilly to investigate the application of its peptide delivery technology to certain Lilly therapeutic candidates.

Entrega’s technology platform is an innovative approach to oral delivery which uses a proprietary, customizable hydrogel dosage form to control local fluid microenvironments in the GI tract to both enhance absorption and reduce the variability of drug exposure. To validate its technology, Entrega generated proof-of-concept data demonstrating delivery of therapeutic peptides into the bloodstream of large animals.